Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 Meeting Abstract
| Authors: | Brahmer, J. R.; Ciuleanu, T. E.; Schenker, M.; Audigier-Valette, C.; Zurawski, B.; Linardou, H.; Kim, S. W.; Otterson, G. A.; Salman, P.; De La Mora Jimenez, E.; Lesniewski-Kmak, K.; Ahmed, S.; Albert, I.; Barlesi, F.; Feeney, K.; Frickhofen, N.; Li, A.; Sun, P.; Hellmann, M. |
| Abstract Title: | Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 |
| Meeting Title: | ESMO Immuno-Oncology Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2020 Dec 9-12 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-12-01 |
| Start Page: | S1444 |
| End Page: | S1445 |
| Language: | English |
| ACCESSION: | WOS:000600992500068 |
| DOI: | 10.1016/j.annonc.2020.10.555 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 67P -- Source: Wos |
